

A² accord sub
and a pharmaceutically acceptable carrier.

26. sub 26. (Amended) A method of treating nasal polyps, comprising administering an epidermal growth factor receptor (EGF-R) antagonist that binds an EGF-R to a patient suffering nasal polyps in an amount effective to reduce goblet cell hyperplasia. *From*